Study	Reason for exclusion
Bruner	2007 This report describes quality of life in the GOG 122 trial. These data were included in the review but the manuscript has no data on the primary outcomes
Brunetto 2000	This was a trial examining the role of ifosfamide for uterine tumours but the morphology was not a simple adneocarinoma. The study population had advanced, persistent or recurrent carcinosarcoma of the uterus. Consequently the data were excluded as they do not address the primary management of a women presenting with a new cancer:
Deng 2000	This trial examined the effect of radiotherapy and chemotherapy on uterine morphology. It is not included in the analyses because there are no outcome data This study reported on the histological changes in 58 women treated for endometrial carcinoma with Estramustine phosphate (EMP) or radiotherapy. Estramustine (Emcyt, Estracit) is a chemotherapy agent commonly used to treat prostate cancer derived from estradiol with a nitrogen mustard-carbamate ester moiety that makes it an alkylating antineoplastic agent similar to mechlorethamine, with oestrogen-induced specificity. Women were randomly divided into three groups and clinically observed. Twenty-one women allocated oral Estramustine had 280 mg twice daily for 21 days before surgery and 19 women allocated radiotherapy received preoperative intra-cavity irradiation with half of the standard dosage. The control group involved 18 women who received surgical operation alone. The microscopic changes induced by irradiation were much heavier than those induced by chemotherapy. 5/21 women given Estramustine were found with no tumour lesion in the post operation samples, all of those five cases had strongly positive oestrogen receptors (++) and four of the five cases were well differentiated tumours before chemotherapy. In radiotherapy group, the tumour lesion disappeared in 6/19 cases, and five were moderately differentiated. No histopathological changes were seen in control group. Immunohistochemical tests revealed a significant decrease in oestrogen receptor staining after Estramustine and a decrease in ki- 67 index, especially for the oestrogen receptor positive tumours. The ki-67 index reduced significantly from 49.5% before to 35.1% after medication (P < 0.05).
Chauvergne 2008	This study compared different chemotherapy regimens but was excluded as the treatment allocation did not use a random allocation program
GCSF	The study population had advanced endometrial carcinoma, and the trial did not focus on the primary treatment after hysterectomy
GOG 107	This phase III trial examined the addition of doxorubicin to cisplatin in advanced endometrial carcinoma
GOG 156	The trial was never completed due to poor accrual
GOG 194	The trial was never completed due to poor accrual
Fujimura 2000	This study compared different chemotherapy regimens but is excluded as the treatment allocation did not involve a group that was not given chemotherapy The trial compared the outcome after randomly allocating women with deeply invasive (old stage 1C) endometrial endometrioid adenocarcinoma after hysterectomy either adjuvant CAP (cyclophosphamide, pirarubicin and cisplatin) or EP (etoposide and cisplatin). The five-year survival rate was 88.4% in the CAP group and 95.1% in the EP group; the difference between the two groups was not significant (P = 0.3496). The disease-free survival rate was 80.3% in the CAP group and 84.8% in the EP group (nonsignificant: P = 0.4533)
Omura	This was a study of women with stage I and II uterine sarcoma who were randomly allocated Doxorubicin (adriamycin) or no adjuvant chemotherapy. Participants did not have endometrial cancer
Samuels 2004	This was a randomised study of trabectedin given by different dosing schedules in patients with uterine leiomyosarcomas or liposarcomas, not cancers
Sutton 2000	This was a randomised trial comparing ifosfamide with ifosfamide + cisplatin involving 194 women with advanced or recurrent carcinosarcoma no longer amenable to control by surgery or radiotherapy
GOG 161	Phase III trial studied the addition of ifosfamide to paclitaxel in advanced uterine carcinosarcoma
Aapro 2003	This study recruited women with advanced inoperable or recurrent endometrial cancer and they were randomly assigned doxorubicin alone or in combination with cisplatin
Cohen 1984	This study recruited women with advanced, recurrent or residual endometrial adenocarcinoma considered incurable by radiation or surgery. Women were randomised to melphalan, 5-fluorouracil and megace or doxorubicin, cyclophosphamide and 5-fluorouracil
Edmonson 1987	This study recruited women with advanced cancer. Women with progestin-refractory, metastatic endometrial cancer were randomised to receive cisplatin alone or cisplatin in combination with doxorubicin and cyclophosphamide
Fleming 2004a	This study recruited women with advanced (stage III, IV) or recurrent endometrial cancer. They were randomised to receive doxorubicin and cisplatin or doxorubicin, cisplatin and paclitaxel with Granulocyte colony stimulating factor support
Fleming 2004b	This study recruited women with primary stage III, stage IV or recurrent endometrial carcinoma. They were randomised to receive doxorubicin and cisplatin or doxorubicin, paclitaxel and G-CSF support
Gallion 2003	This study recruited women with primary stage II, IV or recurrent endometrial carcinoma. They were randomised to standard-timed doxorubicin or circadian-timed doxorubicin and cisplatin
Horton 1978	This small study recruited women with measurable local extension or metastases not amenable to cure by surgery or radiotherapy. The women were randomised to receive doxorubicin or cyclophosphamide
Long 1995	This small study described in abstract form recruited women with advanced cancer. They were randomised to receive doxorubicin and cisplatin or doxorubicin, cisplatin, methotrexate and vinblastine
Pawinski 1999	This study recruited women with recurrent or metastatic disease. They were randomised to receive cyclophosphamide or ifosfamide
Thigpen 1994	This study recruited women with advanced cancer. Women had advanced or recurrent endometrial carcinoma no longer amenable to surgery or radiotherapy and were randomised to receive doxorubicin alone or in combination with cyclophosphamide
Thigpen 2004	This study recruited women with advanced cancer or recurrent endometrial carcinoma. They were randomised to treatment with doxorubicin alone or in combination with cisplatin